Nexavar (sorafenib tosylate) — United Healthcare
soft tissue sarcoma
Preferred products
- Gleevec (imatinib)
- Sutent (sunitinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Initial criteria
- Diagnosis of angiosarcoma OR desmoid tumors / aggressive fibromatosis OR (progressive GIST AND History of failure, contraindication, or intolerance to Gleevec (imatinib) OR Sutent (sunitinib) OR Stivarga (regorafenib) OR Qinlock (ripretinib)) OR solitary fibrous tumor/hemangiopericytoma
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Nexavar therapy
Approval duration
12 months